Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan
Domenico Aquino 1 , Anna Luisa Di Stefano 2 , Alessandro Scotti 1 , Lucia Cuppini 1 , Elena Anghileri 3 , Gaetano Finocchiaro 3 , Maria Grazia Bruzzone 1 , and Marica Eoli 3
Neuroradiology, Fondazione IRCCS Istituto
Neurologico Carlo Besta, Milan, Italy,
Neurology, IRCCS Istituto Neurologico Nazionale
C.Mondino, Pavia, Italy,
Neuro-Oncology, Fondazione IRCCS Istituto Neurologico
Carlo Besta, Milan, Italy
Perfusion weighted imaging may be useful in the early
assessment of response to angiogenesis inhibitors. Aim
of this work is to compare Parametric Response Maps with
the Region Of Interest approach in the analysis of tumor
changes induced by bevacizumab and irinotecan in 42
recurrent glioblastomas, and to evaluate if changes in
tumor CBV measured by perfusion MRI may predict clinical
outcome. An increased CBV (> 18%) in PRM after 8 weeks
of treatment was associated with increased PFS and OS.
The presence of two non-contiguous lesions and
multifocal disease at baseline were independent
predictors of shorter PFS and OS.
This abstract and the presentation materials are available to members only;
a login is required.